Biocon Ltd
Biocon Ltd (BIOCON) last reported results for the quarter ended Jun 2026, with sales of ₹4,336 crore and net profit of ₹137 crore. The stock last traded at ₹369, a market capitalisation of ₹60,193 crore, on a P/E of 82.7. Over the past 52 weeks the stock has ranged between ₹338 and ₹447. Figures are as of 6 Oct 2026 and are not real time.
Biocon Ltd share price and key metrics
- Current price
- ₹369
- Market cap
- ₹60,193 cr
- Stock P/E
- 82.7
- Book value
- ₹210
- ROE
- 1.40%
- ROCE
- 3.61%
- Dividend yield
- 0.14%
- 52w high / low
- 447/338
Metrics as of 6 Oct 2026. Not real time.
Track Biocon Ltd
Cruxal reads every Biocon Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Biocon Ltd growth and returns
- 10 Years
- 18%
- 5 Years
- 19%
- 3 Years
- 15%
- TTM
- 10%
- 10 Years
- 1%
- 5 Years
- -12%
- 3 Years
- -15%
- TTM
- 100%
- 10 Years
- 9%
- 5 Years
- 1%
- 3 Years
- 12%
- 1 Year
- 6%
- 10 Years
- 6%
- 5 Years
- 4%
- 3 Years
- 3%
- Last Year
- 1%
Biocon Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4,336 cr, up 10.0% from ₹3,942 cr a year earlier. Net profit was ₹137 cr, up 53.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 |
| Expenses | 2,905 | 3,070 | 3,339 | 3,176 | 3,460 | 3,340 | 3,496 | 3,489 |
| Operating profit | 685 | 752 | 1,078 | 766 | 835 | 834 | 1,020 | 847 |
| OPM % | 19% | 20% | 24% | 19% | 19% | 20% | 23% | 20% |
| Other income | 58 | 53 | 57 | 62 | 81 | -176 | -28 | 41 |
| Interest | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 |
| Depreciation | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 |
| Profit before tax | 98 | 156 | 487 | 97 | 171 | -68 | 248 | 128 |
| Tax % | 72% | 48% | 6% | 8% | 22% | -24% | 20% | -7% |
| Net profit | 27 | 81 | 459 | 89 | 133 | -52 | 199 | 137 |
| EPS (₹) | -0.13 | 0.21 | 2.87 | 0.23 | 0.63 | 1.08 | 0.78 | 0.87 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Biocon Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,891 | 4,123 | 5,514 | 6,300 | 7,143 | 8,184 | 11,174 | 14,756 | 15,262 | 16,927 | 17,321 |
| Operating profit | 980 | 829 | 1,394 | 1,604 | 1,581 | 1,793 | 2,412 | 3,216 | 3,254 | 3,471 | 3,536 |
| OPM % | 25% | 20% | 25% | 25% | 22% | 22% | 22% | 22% | 21% | 21% | 20% |
| Net profit | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 369 | 416 |
| EPS (₹) | 5.10 | 3.10 | 7.54 | 6.24 | 6.17 | 5.40 | 3.85 | 8.52 | 8.44 | 2.38 | 3.36 |
TTM is the trailing twelve months to the most recent quarter.
Biocon Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 810 |
| Reserves | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 | 33,221 |
| Borrowings | 2,302 | 2,264 | 2,422 | 2,715 | 4,481 | 5,147 | 18,019 | 16,277 | 18,362 | 15,434 |
| Other liabilities | 2,254 | 2,545 | 3,672 | 4,993 | 6,382 | 6,763 | 15,856 | 19,693 | 18,534 | 13,943 |
| Total liabilities | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 63,409 |
| Fixed assets | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 | 36,486 |
| CWIP | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 | 6,987 |
| Investments | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 | 1,779 |
| Other assets | 3,676 | 4,312 | 4,811 | 5,281 | 7,374 | 8,074 | 12,888 | 16,117 | 16,941 | 18,157 |
| Total assets | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 63,409 |
As reported by the company. Total assets equal total liabilities by construction.
Biocon Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,852 | 2,954 | 4,061 | 1,994 |
| Cash from investing | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 | -1,883 |
| Cash from financing | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 | -924 |
| Net cash flow | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 | -812 |
| Free cash flow | 32 | -251 | -337 | -546 | -577 | -746 | 129 | 1,046 | 1,718 | 82 |
| CFO / operating profit | 86% | 104% | 104% | 101% | 86% | 80% | 86% | 101% | 139% | 64% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Biocon Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 12% | 8% | 13% | 13% | 10% | 9% | 6% | 6% | 6% | 4% |
| Debtor days | 83 | 94 | 86 | 71 | 77 | 92 | 117 | 154 | 131 | 129 |
| Inventory days | 160 | 161 | 199 | 263 | 304 | 309 | 423 | 368 | 346 | 390 |
| Days payable | 187 | 224 | 231 | 243 | 246 | 216 | 383 | 467 | 460 | 434 |
| Cash conversion cycle | 57 | 31 | 53 | 91 | 134 | 184 | 157 | 55 | 18 | 85 |
| Working capital days | 24 | 6 | -2 | -31 | 8 | 71 | 3 | -68 | -63 | -17 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Biocon Ltd shareholding pattern
Promoters held 44.68% at Jun 2026, down from 54.45% at Jun 2025. FIIs 8.14% and DIIs 23.33%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 60.64% | 60.64% | 60.64% | 54.45% | 54.45% | 54.45% | 44.91% | 44.68% |
| FIIs | 5.93% | 5.66% | 5.67% | 6.04% | 6.61% | 7.39% | 7.52% | 8.14% |
| DIIs | 14.44% | 15.36% | 15.73% | 22.83% | 22.06% | 21.67% | 24.01% | 23.33% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% | 0.03% | 0.05% | 0.05% |
| Public | 18.74% | 18.11% | 17.77% | 16.51% | 16.70% | 16.34% | 23.40% | 23.75% |
| No. of shareholders | 4,39,503 | 4,27,705 | 4,24,297 | 4,28,131 | 4,13,191 | 3,94,279 | 3,86,593 | 3,92,833 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Biocon Ltd corporate filings
- Biocon Ltd Discloses Regulatory Filing; No Financial Impact IndicatedCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has made a regulatory disclosure pursuant to SEBI Listing Regulations on…
Read the full analysis - Biocon grants employee stock options under Unity LTIP 2026Company Updatelow impact
Cruxal's analysis: Biocon Ltd has announced the grant of employee stock options under its Unity Long Term…
Read the full analysis - Intimation regarding closure of Trading WindowInsider Trading / SASTlow impact
- Biocon Ltd announces routine Company Secretary updateCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has issued a corporate update regarding the Company Secretary position. This…
Read the full analysis - Biocon Ltd files routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Biocon Ltd has submitted a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Biocon Limited initiates final dividend payout of 0.50 INR per share for FY 2025-26Company Updatelow impact
Cruxal's analysis: Biocon Limited has formally initiated the remittance of a final dividend of 0.50 INR per…
Read the full analysis - Biocon Ltd schedules meetings with institutional investorsCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has issued an intimation regarding scheduled meetings with various analysts…
Read the full analysis - Biocon Ltd: Submission of Press Release under Regulation 30Company Updatelow impact
Cruxal's analysis: Biocon Ltd has filed a press release under Regulation 30 of the SEBI (LODR) Regulations…
Read the full analysis - Biocon Ltd schedules meetings with institutional investorsCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has issued an intimation regarding upcoming scheduled meetings with various…
Read the full analysis - Biocon Limited confirms remittance of final dividend of INR 0.50 per share for FY 2025-26Company Updatelow impact
Cruxal's analysis: Biocon Limited has formally intimated the remittance of a final dividend of INR 0.50 per…
Read the full analysis - Mylan Inc. Files Clarification Regarding Complete Exit from Biocon LimitedInsider Trading / SASTlow impact
Cruxal's analysis: Biocon Limited has received a formal clarification from Mylan Inc. regarding its…
Read the full analysis - Biocon Ltd issues routine company statementCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has released a general company statement dated August 25, 2026. The disclosure…
Read the full analysis - Biocon Ltd issues general company statementCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has released a general company statement dated August 18, 2026. The filing…
Read the full analysis - Biocon Ltd announces scheduled analyst/investor meetCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has issued an intimation regarding an upcoming analyst/investor meet. The…
Read the full analysis - Biocon Q1 FY27 Earnings Call Transcript: Focus on Profitable Growth and Biosimilar ExpansionCompany Updatehigh impact
Cruxal's analysis: Biocon Limited reported a 10% year-on-year growth in operating revenue for Q1 FY27, with…
Read the full analysis - Biocon Limited announces successful conclusion of 48th AGM and approval of Long Term Incentive Plan 2026AGM/EGMmedium impact
Cruxal's analysis: Biocon Limited has successfully concluded its 48th Annual General Meeting held on August…
Read the full analysis - Biocon Ltd schedules analyst/investor meetCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has issued an intimation regarding an upcoming analyst/investor meet. The…
Read the full analysis - Biocon Ltd: Newspaper publication of financial results noticeCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has published a statutory newspaper advertisement regarding its financial…
Read the full analysis - Biocon Limited announces resignation of statutory auditors for material subsidiary Biocon Biologics Limited due to mandatory rotationCompany Updatelow impact
Cruxal's analysis: Biocon Limited has disclosed that B S R & Co. LLP has resigned as the statutory auditor…
Read the full analysis - Biocon Ltd announces completion of tenure of statutory auditorsCompany Updatelow impact
Cruxal's analysis: Biocon Ltd has formally notified the completion of the tenure of its statutory auditors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.